{"title":"Feasibility and clinical utility of home-based fecal immunochemical testing for self-monitoring of disease activity in ulcerative colitis.","authors":"Yuki Aoyama, Toshihiro Inokuchi, Sakiko Hiraoka, Mikako Ishiguro, Shoko Igawa, Keiko Takeuchi, Masahiro Takahara, Junki Toyosawa, Yasushi Yamasaki, Hideaki Kinugasa, Motoyuki Otsuka","doi":"10.1093/crocol/otag025","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Home-based quantitative fecal calprotectin testing has been used to improve the prognosis of ulcerative colitis (UC) patients. However, its cost and the need for specific measurement devices limit accessibility. This study explored the potential of the home-based fecal immunochemical test (FIT) for self-monitoring in patients with UC.</p><p><strong>Methods: </strong>In this prospective cohort study, we recruited patients in clinical remission who were scheduled for colonoscopy between October 2020 and October 2021. We evaluated the correlation between home-based qualitative FIT results obtained using a commercially available kit and hospital-based quantitative fecal markers, endoscopic activity, and treatment intensification. We also assessed the feasibility of continued home-based FIT.</p><p><strong>Results: </strong>Among the 54 enrolled patients, 38 tested negative and 16 tested positive using the home-based FIT. The FIT-negative patients had significantly lower hospital-based FIT and fecal calprotectin levels than the FIT-positive patients (<i>P</i> < .0001 and <i>P</i> = .0029, respectively). The accuracy of home-based FIT for predicting endoscopic remission was 0.83, which was comparable to that of hospital-based FIT (0.85) and fecal calprotectin (0.79). None of the 38 FIT-negative patients required intensification of treatment. Among the 20 patients eligible for continued home-based FIT, the adherence rate over one year was 97.0% (82.1%-100%). Notably, none of the 8 FIT-negative patients experienced clinical relapse, whereas those with at least one FIT-positive showed a higher tendency for clinical relapse (<i>P </i>= .055).</p><p><strong>Conclusions: </strong>Home-based FIT is a feasible, accurate, and well-accepted tool for monitoring remission in UC and is comparable to hospital-based fecal markers (UMIN000040572).</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 2","pages":"otag025"},"PeriodicalIF":1.8000,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263107/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Crohn's & Colitis 360","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/crocol/otag025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Home-based quantitative fecal calprotectin testing has been used to improve the prognosis of ulcerative colitis (UC) patients. However, its cost and the need for specific measurement devices limit accessibility. This study explored the potential of the home-based fecal immunochemical test (FIT) for self-monitoring in patients with UC.
Methods: In this prospective cohort study, we recruited patients in clinical remission who were scheduled for colonoscopy between October 2020 and October 2021. We evaluated the correlation between home-based qualitative FIT results obtained using a commercially available kit and hospital-based quantitative fecal markers, endoscopic activity, and treatment intensification. We also assessed the feasibility of continued home-based FIT.
Results: Among the 54 enrolled patients, 38 tested negative and 16 tested positive using the home-based FIT. The FIT-negative patients had significantly lower hospital-based FIT and fecal calprotectin levels than the FIT-positive patients (P < .0001 and P = .0029, respectively). The accuracy of home-based FIT for predicting endoscopic remission was 0.83, which was comparable to that of hospital-based FIT (0.85) and fecal calprotectin (0.79). None of the 38 FIT-negative patients required intensification of treatment. Among the 20 patients eligible for continued home-based FIT, the adherence rate over one year was 97.0% (82.1%-100%). Notably, none of the 8 FIT-negative patients experienced clinical relapse, whereas those with at least one FIT-positive showed a higher tendency for clinical relapse (P = .055).
Conclusions: Home-based FIT is a feasible, accurate, and well-accepted tool for monitoring remission in UC and is comparable to hospital-based fecal markers (UMIN000040572).
背景：基于家庭的定量粪便钙保护蛋白检测已被用于改善溃疡性结肠炎（UC）患者的预后。然而，其成本和对特定测量设备的需求限制了其可及性。本研究探讨了家庭粪便免疫化学测试（FIT）在UC患者自我监测中的潜力。方法：在这项前瞻性队列研究中，我们招募了计划在2020年10月至2021年10月期间进行结肠镜检查的临床缓解患者。我们评估了使用市售试剂盒获得的基于家庭的定性FIT结果与基于医院的定量粪便标志物、内窥镜活动和治疗强化之间的相关性。我们亦评估继续以家庭为基础的FIT的可行性。结果：在54例入组患者中，38例使用家庭FIT检测为阴性，16例检测为阳性。FIT阴性患者的医院基础FIT和粪便钙保护蛋白水平明显低于FIT阳性患者(P P =。0029年,分别)。基于家庭的FIT预测内镜缓解的准确性为0.83，与基于医院的FIT（0.85）和粪便钙保护蛋白（0.79）相当。38例fit阴性患者均无需加强治疗。在20名符合继续居家FIT的患者中，一年以上的依从率为97.0%（82.1%-100%）。值得注意的是，8例fit阴性患者均未出现临床复发，而至少1例fit阳性患者的临床复发倾向较高（P = 0.055）。结论：基于家庭的FIT是一种可行、准确且被广泛接受的监测UC缓解的工具，与基于医院的粪便标志物（UMIN000040572）相当。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
